Identifying Potential Effects of Liraglutide on Degenerative Changes

Sponsor
University of Aarhus
Study ID
NCT01469351
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Liraglutide — DRUG
    Liraglutide (Victoza ®), human GLP-1 analog produced using recombinant DNA technology in saccharomyces cerevisiae. Victoza ® is registered and approved for the treatment of type 2 diabetes. Victoza ® stimulates glucose-dependent insulin secretion from β-cells and inhibits glucagon secretion, slows ventricle emptying and reduces body weight and body fat mass by affecting appetite regulation. Form of administration: Liraglutide is a clear injection fluid, which comes in a prefilled disposable pen. 1 ml contains 6 mg of liraglutide in sterile water. There is added disodium phosphate and propylene glycol and the preservative phenol. A filled pen contains 18mg liraglutide in 3ml. NovoFine® needles are used.
  • non-active study drug — DRUG
    placebo

Study Details

Today Alzheimers disease can not be cured. Animal experiments have shown that the hormone GLP-1 can improve memory in Alzheimer-prone mice. The investigators hypothesis is that a 6-month treatment with the GLP-1 receptor stimulating drug liraglutide will reduce the intracerebral amyloid deposition in the central nervous system (CNS) in patients with Alzheimer's disease (AD) and thereby reduce the clinical symptoms of the disease.

Key Dates

Start date
Jan 31, 2012
Status verified
Apr 2013
Primary completion
Apr 30, 2013
Completion
Apr 30, 2013

Study Design

Enrollment
34 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Drug
    the GLP-1 receptor analog liraglutide is the active drug. The dose is 1.8mg daily
  • Placebo Comparator: placebo
    non active intervention

Primary Outcome Measure

PIB PET scan [ Time Frame: PIB PET-scan at baseline and after 26 weeks ]

Related Studies